title: Virological profile of pregnant HIV positive women with high levels of CD4 count in low income settings: can viral load help as eligibility criteria for maternal triple ARV prophylaxis (WHO 2010 option B)?
abstract: BACKGROUND
  The objective of the study was to determine HIV-1 RNA load profile during pregnancy and assess the eligibility for the maternal triple antiretroviral prophylaxis. It was an observational cohort of pregnant HIV positive women ignorant of antiretroviral therapy with CD4 cell count of > 350/mm(3) METHODS: Routine CD4 cell count assessment in HIV positive pregnant women completed by non exclusive measurement of the viral load by PCR /ARN in those with CD4 cell count > 350/mm(3).
  
  
  METHODS
  highly active antiretroviral therapy prior to pregnancy.
  
  
  RESULTS
  Between January and December 2010, CD4 cell count was systematically performed in all pregnant women diagnosed as HIV-infected (n=266) in a referral center of 25 antenatal clinics. 63% (N=170) had CD4 cell count > 350/mm(3), median: 528 (IQR: 421-625). 145 underwent measurement of viral load by PCR/RNA at a median gestational of 23 weeks of pregnancy (IQR: 19-28). Median viral load 4.4 log(10)/ml, IQR (3.5-4.9).19/145(13%) had an undetectable viral load of = 1.8 log(10)/ml. 89/145(61%) had a viral load of = 4 log(10)/ml and were eligible for maternal triple ARV prophylaxis.
  
  
  CONCLUSIONS
  More than 6 in 10 pregnant HIV positive women with CD4 cell count of > 350/mm(3) may require triple antiretroviral for prophylaxis of MTCT. Regardless of cost, such results are conclusive and may be considered in HIV high burden countries for universal access to triple antiretroviral prophylaxis in order to move towards virtual elimination of HIV MTCT.
authors.affiliation: National Social Insurance Fund Hospital, Yaoundé, Cameroon.
authors.forename: Anne Esther
authors.initials: AE
authors.lastname: Njom Nlend
authors.forename: Chantal
authors.initials: C
authors.lastname: Same Ekobo
authors.forename: Suzie Tetang Ndiang
authors.initials: ST
authors.lastname: Moyo
authors.forename: Gisele Chewa
authors.initials: GC
authors.lastname: Nguetcheng
authors.forename: Peter
authors.initials: P
authors.lastname: Ngang
authors.forename: Sidonie
authors.initials: S
authors.lastname: Lyeb
authors.forename: Luc
authors.initials: L
authors.lastname: Meka
authors.forename: Martin
authors.initials: M
authors.lastname: Baane
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission*; D006679:HIV Seropositivity / Q000276:immunology / Q000821:virology*; D015497:HIV-1; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011203:Poverty; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000821:virology*; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents